Aisling Capital

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by

2.0
(3)
Recommend to another founder 40%
Add your review

Independent rating of Aisling Capital VC fund

Overall rating:
2.0
(3)
Recommend to another founder: 40%
Team quality
2.0
Professionalism
Personal qualities
None
Integrity
None
Respect and decency
None
Experience
Relevant expertise
None
Investment process
Not reviewed
Approachability
None
Clarity of the process
None
Speed of the process
None
Responsiveness
None
Ease of the process
None
Due diligence
None
Value add
2.0
Supportiveness
Value add beyond financing
None
Board activity
None
Terms
Founder friendly
None
Help with follow-up rounds
None

About Aisling Capital VC fund

Website:
http://www.aislingcapital.com
Founded:
2000
Number of funds:
3
Number of investments:
112
Number of exits:
58
Headquarters:
New York, United States
Organization type:
Private Equity Firm

How Aisling Capital VC fund invests

Rounds:
Series B, Series A, Series C
Average ticket size:
26.8M USD
Smallest investment:
16M USD
Biggest investment:
49.1M USD
Would lead round:
Yes
Would coinvest:
Yes
Countries where invested:
United States, Switzerland
Sectors of interest:
Biotechnology, Therapeutics, Life Science, Pharmaceutical, Medical, Health Care, Biopharma

Portfolio - latest investments by Aisling Capital VC fund
Elevation Oncology
Biomea Fusion
Reneo Pharmaceuticals
Antios Therapeutics
Talaris Therapeutics
Garuda Therapeutics
Wugen
Monte Rosa Therapeutics

Founders' reviews of Aisling Capital VC fund

Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Aisling Means 'Vision' in This Case Its a Nightmare
I've successfully pitched and then worked with this fund in a portfolio company. They aren't good. Bad behavior at the Board level and usual VC tricks of changing terms at last moment are their bread and butter. Dennis Purcell is OK on a one to one level. Dov Goldstein has a very bad reputation in the NYC, NJ and PA areas. He's immature and brings no business nor management value to portfolio companies - Unless you're really desperate - go elsewhere.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Create a free account
Worth Passing, Bad Terms, No Operational Experience
Generally the team of Dennis Purcell (legend within the industry), Andrew Schiff (lightweight) and Steve Elms (realtor) are average to good. Tony Sun is particularly good. Unfortunately the weak link in the partnership is Dov Goldstein who is nasty, bullying and deceitful. Unless you're dealing with Dennis or Tony, avoid this crew.
Team quality
2.0
Professionalism
Experience
Investment process
Not reviewed
Value add
2.0
Supportiveness
Terms
Recommend to another founder 40%
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Create a free account
Aisling Means 'Vision' in This Case Its a Nightmare
I've successfully pitched and then worked with this fund in a portfolio company. They aren't good. Bad behavior at the Board level and usual VC tricks of changing terms at last moment are their bread and butter. Dennis Purcell is OK on a one to one level. Dov Goldstein has a very bad reputation in the NYC, NJ and PA areas. He's immature and brings no business nor management value to portfolio companies - Unless you're really desperate - go elsewhere.
Similar funds